Genitourinary Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Genitourinary
| Protocol | SWOG S1802 |
|---|---|
| Cancer Type: | Metastatic Prostate Cancer |
| Fast Facts |
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
| Protocol | NRG GU009 |
|---|---|
| Cancer Type: | HIGH RISK PROSTATE CANCER |
| Fast Facts |
PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)
| Protocol | NRG GU010 |
|---|---|
| Cancer Type: | Prostate Cancer |
| Fast Facts |
NRG-GU010 - Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
| Protocol | NRG GU011 |
|---|---|
| Cancer Type: | Prostate |
| Fast Facts |
NRG-GU011, A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)
| Protocol | NRG GU013 |
|---|---|
| Cancer Type: | Prostate |
| Fast Facts |
NRG-GU013, The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S2200 |
|---|---|
| Cancer Type: | Renal Cell |
| Fast Facts |
SWOG - S2200, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2).”
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S1937 |
|---|---|
| Cancer Type: | Metastatic Urothelial Carcinoma |
| Fast Facts |
A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | COG AREN2231 |
|---|---|
| Cancer Type: | Genitourinary-renal-Wilms |
| Fast Facts |
AREN2231, Risk Adapted Treatment for Unilateral Favorable Histology Wilms Tumor (FHWT)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | COG AREN1921 |
|---|---|
| Cancer Type: | Wilms |
| Fast Facts |
COG-AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Patients must be ≤ 30 years old at study enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
